Study Overview: This study looks at the long-term safety and effects of a medicine called Livmarli for people with Alagille Syndrome (ALGS). ALGS is a rare and complicated genetic disorder that affects many parts of the body and causes a buildup of bile, which can make skin very itchy (pruritus). Livmarli helps reduce this itchiness by stopping the body from absorbing too much bile.

What is Livmarli? It's a special medicine approved by the FDA for treating itchy skin in kids who are at least 3 months old and have ALGS. Livmarli is not absorbed much into the body, which helps make it safer for long-term use.

Key Points:

• Participants in this study must have a confirmed diagnosis of ALGS and be prescribed Livmarli.
• Those previously involved in Livmarli trials or who took certain investigational drugs cannot join.
• Participants must provide consent and must not have any conditions that interfere with the study.

This study is important for understanding how Livmarli works over time, ensuring it is safe and beneficial for patients with ALGS.